TY - JOUR T1 - Adapting Lot Quality Assurance Sampling to accommodate imperfect tests: application to COVID-19 serosurveillance in Haiti JF - medRxiv DO - 10.1101/2020.09.11.20193052 SP - 2020.09.11.20193052 AU - Isabel R. Fulcher AU - Mary Clisbee AU - Wesler Lambert AU - Fernet Renand Leandre AU - Bethany Hedt-Gauthier Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/13/2020.09.11.20193052.abstract N2 - Background Lot Quality Assurance Sampling (LQAS), a tool used for monitoring health indicators in low resource settings resulting in “high” or “low” classifications, assumes that determination of the trait of interest is perfect. This is often not true for diagnostic tests, with imperfect sensitivity and specificity. Here, we develop Lot Quality Assurance Sampling for Imperfect Tests (LQAS-IMP) to address this issue and apply it to a COVID-19 serosurveillance study in Haiti.Development As part of the standard LQAS procedure, the user specifies allowable classification errors for the system, which is defined by a sample size and decision rule. We show that when an imperfect diagnostic test is used, the classification errors are larger than specified. We derive a modified procedure, LQAS-IMP, that accounts for the sensitivity and specificity of a diagnostic test to yield correct classification errors.Application At Zanmi Lasante health facilities in Haiti, the goal was to assess the prior circulation of COVID-19 among healthcare workers (HCWs) using a limited number of antibody tests. As the COVID-19 antibody tests were known to have imperfect diagnostic accuracy, we used the LQAS-IMP procedure to define valid systems for sampling at eleven hospitals in Haiti.Conclusions The LQAS-IMP procedure accounts for imperfect sensitivity and specificity in system design; if the accuracy of a test is known, the use of LQAS-IMP extends LQAS to applications for indicators that are based on laboratory tests, such as COVID-19 antibodies.Key MessagesIt is imperative to account for the sensitivity and specificity of the diagnostic test in serosurveillance studies.For prevalence estimation and inference, adjustments for imperfect testing properties are available to researchers. However, no adjustments currently exist for the design of Lot Quality Assurance Sampling systems, resulting in invalid classification systems when used with an imperfect diagnostic test.When sensitivity and specificity of a diagnostic test is known, Lot Quality Assurance Sampling for Imperfect Tests should be used to determine the sample size and decision rule for a system as it will result in valid classification errors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work did not require IRB approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable https://github.com/isabelfulcher/lqas_imp ER -